Cargando…
Targeting ACE2–RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay
[Image: see text] The COVID-19 pandemic, caused by SARS-CoV-2, is a pressing public health emergency garnering a rapid response from scientists across the globe. Host cell invasion is initiated through direct binding of the viral spike protein to the host receptor angiotensin-converting enzyme 2 (AC...
Autores principales: | Hanson, Quinlin M., Wilson, Kelli M., Shen, Min, Itkin, Zina, Eastman, Richard T., Shinn, Paul, Hall, Matthew D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American
Chemical Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688046/ https://www.ncbi.nlm.nih.gov/pubmed/33330843 http://dx.doi.org/10.1021/acsptsci.0c00161 |
Ejemplares similares
-
Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
por: Hanson, Quinlin M., et al.
Publicado: (2020) -
Comparison of AlphaLISA and RIA assays for measurement of wool cortisol concentrations
por: Peric, T., et al.
Publicado: (2020) -
Development of an AlphaLISA assay for sensitive and accurate detection of influenza B virus
por: Zong, Huijun, et al.
Publicado: (2023) -
Rapid, automated, parallel quantitative immunoassays using highly integrated microfluidics and AlphaLISA
por: Tak For Yu, Zeta, et al.
Publicado: (2015) -
Quantification of Total and Mutant Huntingtin Protein Levels in Biospecimens Using a Novel alphaLISA Assay
por: Baldo, Barbara, et al.
Publicado: (2018)